The reagent a laboratory builds its own test from

What the component is

The classification regulation defines the category. Analyte specific reagents are antibodies, both polyclonal and monoclonal, specific receptor proteins, ligands, nucleic acid sequences and similar reagents.

What makes them that category is the intended use. Through specific binding or chemical reaction with substances in a specimen, they are intended for use in a diagnostic application for identification and quantification of an individual chemical substance or ligand in biological specimens.

They are the building block rather than the finished test. A laboratory takes one and builds an in-house assay around it.

Most sit in class one and are exempt from premarket notification. Some are class two where the analyte is used in blood banking tests already classified that way, and the classification regulation names the guidance documents that apply.

The classification regulation also carves out two buyers from its own scope. Where reagents otherwise meeting the definition are sold to diagnostic manufacturers, or to organizations making tests for non-diagnostic purposes, they fall outside the subpart that would otherwise cover them.

A restricted device, and the list of who may buy one

These reagents are restricted devices under section 520(e) of the statute, and the regulation sets out what that restriction is.

They may only be sold to three groups. In vitro diagnostic manufacturers. Clinical laboratories regulated under the Clinical Laboratory Improvement Amendments as qualified to perform high complexity testing, or clinical laboratories regulated under a named Veterans Health Administration directive. And organizations that use the reagents to make tests for purposes other than providing diagnostic information to patients and practitioners, which the regulation illustrates with forensic, academic, research and other nonclinical laboratories.

The high complexity qualification in the middle item is the substantive one. A laboratory has to hold a specific certification before these components may be sold to it at all.

The restrictions are lifted for two of the three buyers. Where reagents otherwise meeting the definition are sold to diagnostic manufacturers, or to organizations making tests for non-diagnostic purposes, several of the restrictions do not apply.

What survives that carve-out is the definition itself. The material is still an analyte specific reagent, and the restriction lifts because of who receives it and what they do with it, rather than because the substance changed.

What the label has to say, and what the advertising may not

The labeling section sets out eleven items for these reagents, and two of them are sentences printed verbatim.

The first nine are ordinary identification. The proprietary and established names. A declaration of the established name. The quantity, proportion or concentration, with source and activity for a reagent derived from biological material. A statement of purity and quality including a quantitative declaration of any impurities present and the method of analysis or characterization. Warnings and precautions. The date of manufacture and storage instructions. Net quantity of contents. The name and place of business of the manufacturer, packer or distributor. And a lot or control number from which the complete manufacturing history can be determined.

The last two are the ones that state the limits. For class one exempt reagents, the label bears the words that it is an analyte specific reagent and that analytical and performance characteristics are not established. For class two and three reagents, the label bears a longer version naming the approved or cleared test as the exception.

Advertising is regulated in the same direction. Promotional materials have to include the identity and purity of the reagent, including source and method of acquisition, and the identity of the analyte, plus the same prescribed statement. And they shall not make any statement regarding analytical or clinical performance.

The label rules leave room for more detail without requiring it. Labeling may also include information about chemical or molecular composition, nucleic acid sequence, binding affinity, cross-reactivities, and interaction with substances of known clinical significance.

The purity requirement has a shortcut written into it. It can be met by a statement of conformity with a generally recognized and generally available standard containing the same information, and the regulation names several standards bodies as examples.

The sentence that has to appear on the report

The most consequential requirement in the section is not about the component at all. It is about what the laboratory has to tell the person who ordered the test.

The laboratory that develops an in-house test using such a reagent has to inform the ordering person of the result by appending to the test report a prescribed statement. It says that the test was developed and its performance characteristics determined by the named laboratory, and that it has not been cleared or approved by the Food and Drug Administration.

The statement has one carve-out. It does not apply and is not required where results are generated using a test that was cleared or approved in conjunction with review of a class two or class three reagent.

Ordering is restricted too. The regulation states that ordering in-house tests developed using analyte specific reagents is limited to physicians and other persons authorized by applicable state law to order such tests.

The disclosure has one stated exception. It is not applicable or required where test results are generated using a test that was cleared or approved in conjunction with review of a class two or class three reagent.

Put together, three restrictions stack on one test. A restriction on who may buy the component, a restriction on who may order the test, and a required disclosure on the face of every report.

How to read a result that carries that line

The disclosure is not a warning about a laboratory. It is a statement about where the performance figures came from.

A cleared or approved test has had its performance characteristics reviewed by the agency. A test built in-house from these reagents has had them determined by the laboratory that built it, and the required sentence says so in those words.

What that leaves open is comparability. Two laboratories can build tests around the same reagent and report on different scales, because the analytical characteristics were established separately in each place.

The prohibition on performance claims in advertising points the same way. Where the regulation forbids a component maker from stating analytical or clinical performance, it is because that performance is a property of the assembled test rather than of the reagent in the bottle.

For anyone reading a laboratory report, the practical value of the rule is that the report itself is required to disclose which kind of test produced it. The sentence is at the bottom of the page by regulation, not by courtesy.

It is also worth being clear about what the disclosure is not. It is not a statement that a result is wrong, and it is not a statement about the laboratory's competence, which is governed by a separate certification scheme. It records who established the performance figures, and leaves the reader to weigh that.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. 21 CFR 809.30 — Restrictions on the sale, distribution and use of analyte specific reagents, read in full for the three categories of permitted buyer, the advertising restrictions, the prescribed report statement, and the limit on who may order an in-house test — Office of the Federal Register, Electronic Code of Federal Regulations, September 2026
2. 21 CFR 809.10 paragraph (e) — Labeling for analyte specific reagents, read for the eleven required items including the purity and impurity declaration and the two prescribed statements for class I exempt and for class II and III reagents — Office of the Federal Register, Electronic Code of Federal Regulations, September 2026
3. 21 CFR 864.4020 — Analyte specific reagents, read for the identification of the category, the exclusion from subpart E for reagents sold to diagnostic manufacturers and non-clinical laboratories, and the class I and class II classifications — Office of the Federal Register, Electronic Code of Federal Regulations, September 2026